Nycomed Articles
Takeda completes 75 million-euro Russian pharmaceutical production plant
11 September 2012
EMA backs approval of Revestive, Zinforo and Seebri Breezhaler, but not Elelyso; Hexaxim opinion
25 June 2012
Nycomed debuts Omnaris nasal spray in the UAE
14 March 2012
Costs take toll on earnings from Japan’s Takeda
1 February 2012
Takeda cuts 2,800 jobs as it assimilates Nycomed
19 January 2012
Takeda ends Daxas co-promotion with MSD; Actos law suits
3 January 2012
Nycomed to market Almirall’s Kestine in Southeast Asia markets; files for linaclotide in EU
30 September 2011
EU Commission OKs Takeda’s acquisition of Nycomed
3 August 2011
Takeda denies it is in talks to buy Nycomed
13 May 2011
Nycomed targeted for takeover by Takeda; reports
12 May 2011
Nycomed files for EU appro of SBS drug Revestive
29 March 2011
Nycomed to market Eurand’s Zenpep in Russia-CIS
13 January 2011
Nycomed posts 8.7% sales rise in 3rd-qtr 2010 results, making strong inroads into emerging markets
10 November 2010
Nycomed confirms Chinese acquisition, buying majority stake in Guangdon Techpool Bio-Pharma for around $210 million
1 November 2010
Plentiful opportunities - and also challenges - in the Indian pharmaceutical market, say experts
12 October 2010
Nycomed progresses its BRIC ambitions, soon to announce Chinese acquisition and opening Indian APIs plant in JV with Zydus
4 October 2010
Spiriva a possible alternative therapy for adults with poorly controlled asthma; Daxas reduces harmful lung attacks, ERS conference hears
21 September 2010
Nycomed’s US partner Forest Labs responds to FDA complete response letter for Daxas
14 September 2010
Pantoprazole patent loss still taking toll on Nycomed in second quarter 2010, but underlying growth good
18 August 2010
New European patient survey backs expert call for greater clinical consensus on breakthrough cancer pain
11 June 2010
Nycomed’s 1st-qtr 2010 sales fall 7.6% and EBITDA slumps 24%, impacted by pantoprazole patent expiry
11 May 2010
Ipsen partners with Invida for specialty care drugs in Southeast Asia; Nycomed and GE set up JV for Russia/CIS
27 April 2010
EMEA’s CHMP backs approval of Nycomed’s Daxas; calls for revocation of MA for bufexamac due to high risk of contact allergies
23 April 2010
DURECT and Nycomed amend Posidur deal to separate funding and control of US and EU clinical programs
23 February 2010
Nycomed CEO talks, Obama and Healthcare Reform
26 January 2010
We know Brazilian pharma market is growing rapidly, but what will the next elections bring for Pharma industry
7 December 2009
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
13 November 2009
Nycomed’s cancer pain drug Instanyl cleared for NHS use in Scotland
10 November 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Abbott to buy Solvay pharmaceuticals business for 4.5 billion euros, but will bidding war cease?
28 September 2009
Solvay Pharma unit set to see a bidding war
24 September 2009
Instanyl sets new standard in breakthrough cancer pain, says Nycomed
11 September 2009
Zacks analysts view AstraZeneca/Forest deal favorably
18 August 2009
Nycomed seeks new cash for Solvay buyout –sources?
10 August 2009
Nycomed submits Daxas for EMEA appro
18 May 2009
Wyeth/Altana lose Protonix IP appeal
15 May 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Allergy Thera signs Canadian drug rights to Nycomed
8 April 2009
Nycomed licenses EffRx' effervescent alendronate in $59M deal
19 January 2009
Pharma/biotech mergers and acquisitions in 2008
12 January 2009
NPS initiates US Gattex trial in SBS
8 December 2008
UPDATE: PDCO has good news for Lux Bio and others
8 December 2008
Nycomed's nine-month turnover down 4.1%
24 November 2008
Strong Ph III COPD data for Nycomed's Daxas
10 November 2008
Protherics rockets on bid approaches
1 September 2008
BioSante reacquires Elestrin rights
18 August 2008
Nycomed to pay up to $620M for veltuzumab
21 July 2008
ABPI collaborates with NHS PCT on COPD care
2 June 2008
Lundbeck launches melatonin sleep aid
19 May 2008
Nycomed's FY 2007 EBITDA jumps 31%
24 March 2008
Axis-Shield's PoCs drive 2007 sales up 10%
17 March 2008
Nycomed completes $346M Bradley buy
3 March 2008
Nycomed licenses US rights to ciclesonide drugs to Sepracor in deal worth up to $430M
4 February 2008
Nycomed's Alvesco gets FDA OK for asthma
28 January 2008
Altana benefits show through at Nycomed
26 November 2007
CHMP "thumbs up" for Angiox extension
26 November 2007
Bently gets Spanish OK for five generic drugs
5 November 2007
Nycomed bids $346M for USA's Bradley
5 November 2007
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
